Survey of practicing cardiologists in Maryland on their choice of thrombolytic therapy for acute myocardial infarction.
In November 1990, we surveyed 160 practicing community cardiologists in the state of Maryland and 20 academic cardiologists at the University of Maryland Medical Center to determine each individual's preference for aggressive versus nonaggressive therapy for various presentations of acute myocardial infarction. The survey was repeated in April 1991 following a report of the results of the Third International Study of Infarct Survival. All 100 responding cardiologists chose aggressive therapy to manage an early (less than 2 hours) acute anterior myocardial infarction in a 50-year-old patient. However, less aggressive therapy was chosen by many community cardiologists for management of early inferior acute myocardial infarction or for elderly patients. Most community cardiologists chose tissue plasminogen activator as their thrombolytic drug of choice, whereas university cardiologists favored streptokinase. Although there were substantial shifts in choice of thrombolytic agent on the repeat survey, most community physicians still chose tissue plasminogen activator over the less expensive streptokinase.
Plotnick
G D
GD
Department of Medicine, University of Maryland, Baltimore.
Ziskind
A A
AA
Vogel
R A
RA
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D016255:Anistreplase / Q000627:therapeutic use; D002309:Cardiology / Q000706:statistics & numerical data*; D016009:Chi-Square Distribution; D006801:Humans; D008396:Maryland; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D013300:Streptokinase / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D015912:Thrombolytic Therapy / Q000379:methods*
D016255:Anistreplase; D013300:Streptokinase